S-B. Kim

1.3k citations

73 papers · 802 indexed · h-index 16

Impact in

Oncology top 5%
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology
Cancer Research top 10%
- Breast Cancer Treatment Studies

Papers in ⓘ

Oncology 52
- Cancer Treatment and Pharmacology 29
- HER2/EGFR in Cancer Research 21
- Cancer Immunotherapy and Biomarkers 11
Pulmonary and Respiratory Medicine 43
- Advanced Breast Cancer Therapies 33
- Lung Cancer Treatments and Mutations 4

Co-authors: S-A. Im (15 shared papers)Seong Hee Ahn (1 shared paper)Hee Jung Shin (1 shared paper)Hyun‐Ha Kim (1 shared paper)Kyung Hae Jung (3 shared papers)Y.H. Park (6 shared papers)Hiroji Iwata (5 shared papers)Javier Cortés (6 shared papers)
Journals: Annals of Oncology (27 papers)Cancer Research (24 papers)ESMO Open (7 papers)Oncogenesis (1 paper)Journal of Gastroenterology and Hepatology (1 paper)
Partner nations: South Korea United States France

In The Last Decade

S-B. Kim

69 papers receiving 785 citations

Peers

Countries citing papers authored by S-B. Kim

Since Specialization

Citations

This map shows the geographic impact of S-B. Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S-B. Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S-B. Kim more than expected).

Fields of papers citing papers by S-B. Kim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S-B. Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S-B. Kim. The network helps show where S-B. Kim may publish in the future.

Co-authors

The 25 scholars most cited alongside S-B. Kim, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with S-B. Kim Line = papers co-authored together S-B. Kim links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 73 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	LBA8_PR Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study Annals of Oncology ·Ken Kato, J-M. Sun, Manan Shah, Peter C. Enzinger, Antoine Adenis, Toshihiko Doi, Takashi Kojima, J-P. Metges, Zhouxiao Li, S-B. Kim, B.C. Chul Cho, Wasat Mansoor, SH Li, Patrapim Sunpaweravong, María Maqueda, Eray Goekkurt, Q. Liu, Sukrut Shah, Pooja Bhagia, Lin Shen	2020	98
2	Comparison of mammography, sonography, MRI and clinical examination in patients with locally advanced or inflammatory breast cancer who underwent neoadjuvant chemotherapy British Journal of Radiology ·Hee Jung Shin, Hyun‐Ha Kim, J.-H Ahn, S-B. Kim, Kyung Hae Jung, G. Gong, B.H. Son, Seong Hee Ahn	2011	84
3	LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study Annals of Oncology ·Javier Cortés, S-B. Kim, W-P. Chung, S-A. Im, Y.H. Park, Roberto Hegg, Minjung Kim, L-M Tseng, Vanessa Petry, C-F. Chung, Hiroji Iwata, E.P. Hamilton, Giuseppe Curigliano, Binghe Xu, C. Lee, Y. Liu, Jillian Cathcart, Emarjola Bako, Sunil Verma, Sara A. Hurvitz	2021	73
4	211MO Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study Annals of Oncology ·M. Martín Jiménez, Elgene Lim, (unknown), Amit Bardia, Jun Wu, Q. Zhang, Zbigniew Nowecki, F. Melo Cruz, Р. Р. Сафин, S-B. Kim, Christian Schem, Alberto J. Montero, Simran Khan, R. Bandyopadhyay, Mahesh Shivhare, Monika Patre, Jorge Martinalbo, Laura Roncoroni, P.D. Pérez-Moreno, Joohyuk Sohn	2022	43
5	Abstract PD3-01: Results from KATE2, a randomized phase 2 study of atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC) Cancer Research ·LA Emens, Francisco J. Esteva, M Beresford, Cristina Saura, Michelino De Laurentiis, S-B. Kim, S-A. Im, Monika Patre, Yibin Wang, Aruna Mani, Hui Liu, Sanne de Haas, Sherene Loi	2019	40
6	ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF Bone Marrow Transplantation ·Jia-Lin Lee, Sung‐Min Kim, S W Kim, Eun‐Kyung Kim, S-B. Kim, Y-K. Kang, Jae‐Yong Lee, M W Kim, Chan‐Jeoung Park, H-S Chi, Jin Won Huh, S-H Kim, Chang‐Ok Suh	2005	33
7	Robust control for a two-axis gimbaled sensor system with multivariable feedback systems IET Control Theory and Applications ·S-B. Kim, S.H. Kim, Y.K. Kwak	2010	31
8	BRCA1 positively regulates FOXO3 expression by restricting FOXO3 gene methylation and epigenetic silencing through targeting EZH2 in breast cancer Oncogenesis ·Chun Gong, Shilin Yao, Ana Gomes, Ellen P.S. Man, Heon‐Jin Lee, Gyungyub Gong, Suhwan Chang, S-B. Kim, Kazunari Fujino, S-W. Kim, S K Park, J W Lee, M H Lee, (unknown), US Khoo, Eric W.‐F. Lam	2016	28
9	Abstract S1-07: A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04) Cancer Research ·Masakazu Toi, SJ Lee, Eun‐So Lee, Shoichiro Ohtani, Y-H Im, S-A. Im, Byeong‐Woo Park, S-B. Kim, Y. Yanagita, Shintaro Takao, Shigeo Ohno, K. Aogi, Hiroji Iwata, A Kim, Hironobu Sasano, Isao Yokota, Yasuo Ohashi, Norikazu Masuda	2016	25
10	377O A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03 Annals of Oncology ·S.A. Hurvitz, Shanu Modi, Wěi Li, Y.H. Park, Wei‐Pang Chung, S-B. Kim, Javier Cortés, Toshinari Yamashita, José Luiz Pedrini, S-A. Im, L-M Tseng, Nadia Harbeck, I. Krop, G. Curigliano, E. Mathias, Jillian Cathcart, A. Cagnazzo, Shahid Ashfaque, Anton Egorov, Fabrice André	2023	24
11	858O Results of KEYNOTE-122: A phase III study of pembrolizumab (pembro) monotherapy vs chemotherapy (chemo) for platinum-pretreated, recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC) Annals of Oncology ·Anthony T.�C. Chan, Victor Lee, R-L. Hong, M-J. Ahn, Wan Qin Chong, S-B. Kim, Gwo Fuang Ho, Priscilla B. Caguioa, Nuttapong Ngamphaiboon, M.A.S. Abdul Aziz, Quan Sing Ng, C-J. Yen, Nopadol Soparattanapaisarn, K.C. Ngan, S.K. Kho, Ramona F. Swaby, Sanatan Saraf, Joy Yang Ge, L.L. Siu	2021	24
12	279P Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (MBC): Updated survival results from a phase II trial (DESTINY-Breast01) Annals of Oncology ·C. Saura Manich, Shanu Modi, Ian E. Krop, Y.H. Park, S-B. Kim, Kenji Tamura, Fabrice André, Hiroji Iwata, (unknown), Junji Tsurutani, Joohyuk Sohn, C. Lee, Y. Liu, Jillian Cathcart, Jasmeet Singh, Toshinari Yamashita	2021	22
13	Highly conserved sequences of three major virion proteins of a Korean isolate of white spot syndrome virus (WSSV) Diseases of Aquatic Organisms ·CH Moon, JW Do, SJ Cha, Won‐Byong Yoon, S-B. Kim, Myung S. Ko, MA Park, JW Kim, Sang-Gyu Sohn, Jun Heon Lee, Jung-Won Park	2003	21
14	PD01-02: Randomized Phase II Study of Dasatinib vs Placebo in Addition to Exemestane in Advanced ER/PR-Positive Breast Cancer [BMS CA180-261 Study]. Cancer Research ·Antonio Llombart‐Cussac, Alessandra Ravaioli, Lewis C. Strauss, Oumar Sy, Fabio Maia Abrahao, WJ Geese, Alain Lortholary, Delphine Réa, J-S Ro, Joohyuk Sohn, S-B. Kim, Giuseppe Curigliano	2011	17
15	181O Interim analysis (IA) of the atezolizumab (atezo) + sacituzumab govitecan (SG) arm in patients (pts) with triple-negative breast cancer (TNBC) in MORPHEUS-pan BC: A phase Ib/II study of multiple treatment (tx) combinations in pts with locally advanced/metastatic BC (LA/mBC) ESMO Open ·Peter Schmid, Sherene Loi, Luis de la Cruz‐Merino, R. Yerushalmi, S-A. Im, A. Sonnenblick, Maria Martinez‐García, Irene Moreno Candilejo, Liam Kennedy, Kristin Griffiths, Richard B. Schwab, Fiona Young, Linchuan Liao, Kelly DuPree, S-B. Kim	2024	16
16	S5-7: A Phase 2, Randomized, Open-Label, Study of Neratinib (HKI-272) vs Lapatinib Plus Capecitabine for 2nd/3rd-Line Treatment of HER2+ Locally Advanced or Metastatic Breast Cancer. Cancer Research ·M Martín, Jacques Bonneterre, CE Geyer, Yasuaki Ito, J. Ro, I. Láng, S-B. Kim, Caroline Germa, Jennifer Vermette, M-L Vo Van, K Wang, K Wang, Ahmad Awada	2011	16
17	139O Final results of the double-blind placebo (PBO)-controlled randomised phase II LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for inoperable locally advanced/metastatic triple-negative breast cancer (mTNBC) Annals of Oncology ·Rebecca Dent, Mafalda Oliveira, Steven J. Isakoff, S-A. Im, Marc Espié, Sibel Blau, Antoinette R. Tan, Cristina Saura, Matthew Wongchenko, N. Xu, Denise Bradley, S-J. Reilly, Aruna Mani, S-B. Kim	2020	14
18	Abstract PD5-01: KEYNOTE-173: Phase 1b multicohort study of pembrolizumab (Pembro) in combination with chemotherapy as neoadjuvant treatment for triple-negative breast cancer (TNBC) Cancer Research ·Peter Schmid, YH Park, Eva Muñoz‐Couselo, S-B. Kim, Joohyuk Sohn, S-A. Im, Esther Holgado, Theodoros Foukakis, Sherko Küemmel, Rebecca Dent, Lei Yin, Yu Ding, Konstantinos Tryfonidis, Javier Cortés	2019	14
19	Abstract P5-18-26: Confirmatory overall survival (OS) analysis of CLEOPATRA: a randomized, double-blind, placebo-controlled Phase III study with pertuzumab (P), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive first-line (1L) metastatic breast cancer (MBC) Cancer Research ·SM Swain, S-B. Kim, J Cortés, Jungsil Ro, Semiglazov Vf, Mario Campone, Eva Ciruelos, J-M Ferrero, Andreas Schneeweiß, A Knott, Elizabeth Clark, G. Ross, MC Benyunes, José Baselga	2012	12
20	Abstract P5-21-01: Cobimetinib combined with paclitaxel as first-line treatment for patients with advanced triple-negative breast cancer (COLET study): Primary analysis of cohort I Cancer Research ·Adam Brufsky, David Miles, Zanete Zvirbule, A. Eniu, Elena López-Miranda, J-H Seo, Michele Orditura, Feng Du, Matthew Wongchenko, Melanie Poulin-Costello, Brian Simmons, Virginia McNally, Sherene Loi, S-B. Kim	2018	11

About S-B. Kim

S-B. Kim is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Otorhinolaryngology and Radiology, Nuclear Medicine and Imaging, having authored 73 papers that have together received 802 indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (33 papers), Cancer Treatment and Pharmacology (29 papers), HER2/EGFR in Cancer Research (21 papers), Breast Cancer Treatment Studies (17 papers), Cancer Immunotherapy and Biomarkers (11 papers), BRCA gene mutations in cancer (4 papers), Esophageal Cancer Research and Treatment (4 papers) and Lung Cancer Treatments and Mutations (4 papers). The work is most often cited by research in Oncology (523 citations), Cancer Research (187 citations), Pulmonary and Respiratory Medicine (300 citations), Radiology, Nuclear Medicine and Imaging (190 citations) and Genetics (59 citations). S-B. Kim has collaborated with scholars based in South Korea, United States and France. Frequent co-authors include S-A. Im, Seong Hee Ahn, Hee Jung Shin, Hyun‐Ha Kim, Kyung Hae Jung, Y.H. Park, Hiroji Iwata, Javier Cortés, Joohyuk Sohn and Jillian Cathcart. Their work appears in journals such as Annals of Oncology, Cancer Research, ESMO Open, Oncogenesis and Journal of Gastroenterology and Hepatology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact